The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Exploring dual-antigen targeting in LBCL: insights into axi-cel plus rituximab data from ZUMA-14
Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, highlights impressive response rate data from the ZUMA-14 trial (NCT04002401), which evaluated axicabtagene ciloleucel (axi-cel) plus rituximab in large B-cell lymphoma (LBCL). Dr Patel notes that this trial paved the way for exploring dual-targeting CD19-CD20 CAR T-cell therapy, which has shown impressive data in randomized trials compared with monospecific CAR T-cells. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I think ZUMA-14 is a really interesting trial. At the time we undertook that trial, we were really just trying to understand targeting two antigens. Do we get a better depth of response? And I think that trial in a lot of ways has served as the basis for what we’re seeing now with dual antigen targeting CAR T-cells. So essentially we were able to see a higher complete response rate...
Yeah, I think ZUMA-14 is a really interesting trial. At the time we undertook that trial, we were really just trying to understand targeting two antigens. Do we get a better depth of response? And I think that trial in a lot of ways has served as the basis for what we’re seeing now with dual antigen targeting CAR T-cells. So essentially we were able to see a higher complete response rate. Yes, you might be able to achieve that with an antibody-based therapy like rituximab, but we probably do better by actually engineering that dual targeting therapy into the CAR T-cell itself. And so now we see several of these CD19-CD20 CAR T-cells with very impressive data now also undergoing randomized trials compared to CD19 mono CARs. So I think that trial really was one of the earliest bases to allow us to advance dual targeting CAR T-cells, which is, I think, going to be a really exciting area.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
